Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of “Hold” from Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have earned an average rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $38.75.

UPB has been the topic of a number of recent research reports. Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a report on Friday, March 27th. Mizuho cut their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $8.46 on Friday. Upstream Bio has a 1 year low of $7.25 and a 1 year high of $33.68. The company’s 50-day moving average is $9.29 and its 200 day moving average is $18.70. The stock has a market capitalization of $460.39 million, a P/E ratio of -2.91 and a beta of 1.28.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The business had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. Research analysts anticipate that Upstream Bio will post -2.99 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC purchased a new stake in Upstream Bio in the first quarter worth about $315,000. California State Teachers Retirement System lifted its stake in shares of Upstream Bio by 170.7% in the first quarter. California State Teachers Retirement System now owns 39,661 shares of the company’s stock worth $357,000 after buying an additional 25,009 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Upstream Bio by 51.2% in the first quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company’s stock worth $138,000 after buying an additional 5,191 shares in the last quarter. Quantinno Capital Management LP lifted its stake in shares of Upstream Bio by 220.4% in the first quarter. Quantinno Capital Management LP now owns 49,389 shares of the company’s stock worth $445,000 after buying an additional 33,974 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Upstream Bio in the first quarter worth approximately $210,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.